Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The main purpose of this protocol is to estimate the percentage of patients with intermediate risk Hodgkin lymphoma who will survive free of disease (Event-free survival) for three years after treatment with multi-agent chemotherapy (Stanford V) and low-dose, tailored-field radiation therapy. The hypothesis being studied is that this treatment will result in more than 80% of patients being alive and free of disease three years after starting treatment.

Official Title

Stanford V Chemotherapy With Low-Dose Tailored-Field Radiation Therapy for Intermediate Risk Pediatric Hodgkin Lymphoma

Eligibility Criteria

Ages Eligible for Study: Younger than 21 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Patient is less than or equal to 21 years of age - Patient has a confirmed diagnosis of previously untreated Hodgkin lymphoma - Has Ann Arbor stage IB, IIIA, or IA/IIA with extranodal extension, multiple nodal involvement (3 or more sites), or bulky mediastinal adenopathy.
Exclusion Criteria:
  1. - Patients with favorable risk features - Patients with unfavorable risk features - Patients who have received prior therapy for Hodgkin lymphoma.


Michael Link

Contact us to find out if this trial is right for you.


Peds Hem/Onc CRAs